Enhanced agglutination method and kit

• US 4,636,479 A
• Filed: 04/20/1983
• Issued: 01/13/1987
• Est. Priority Date: 04/20/1983
• Status: Expired due to Term

• Current Assignee: Lipsome Technology, Inc.
• Original Assignee: Cooper Lipotech Incorporated
• Inventors: Martin, Francis J., Kung, Viola T.
• Primary Examiner(s): Marantz, Sidney
• Application Number:
  US06/486,793
• Time in Patent Office: 1,364 Days
• Field of Search: 436/506-509, 436/512, 436/539, 436/540, 436/808, 436/820, 436/829, 436/520, 436/533, 436/534, 436/808, 436/819, 436/829, 424/85, 435/4, 435/7, 252/316
• US Class Current: 436/533
• CPC Class Codes: G01N 33/54393 Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
• CPC Class Codes: G01N 33/563 involving antibody fragments
• CPC Class Codes: G01N 33/567 utilising isolate of tissue or organ as binding agent
• CPC Class Codes: G01N 33/576 for hepatitis
• CPC Class Codes: Y10S 436/808 Automated or kit
• CPC Class Codes: Y10S 436/819 Multifunctional antigen or antibody
• CPC Class Codes: Y10S 436/829 Liposomes, e.g. encapsulation

Abstract

An enhanced agglutination assay method for determination of a multivalent analyte is disclosed. Analyte is added to agglutinatable particles coated with anti-analyte molecules to produce particle agglutination. The extent of agglutination is enhanced by mixing the particles and analyte with an analyte-binding reagent composed of lipid bodies. The reagent bodies act by promoting multiple analyte bridge connections between individual bridged particles and a reagent body. Also disclosed is a kit containing such particles and reagent.

Claims

1. An enhanced agglutination assay method for determination of a multivalent analyte in a weakly positive analyte-containing sample, said method comprising:

providing an unagglutinated suspension of (a) agglutinatinable particles between about 1 and 20 microns in diameter and having surface-bound anti-analyte molecules effective to produce particle agglutination in the presence of such analyte, and (b) liposomes having surface-bound analyte-binding protein molecules, at an average surface concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule.

adding such analyte-containing sample to the suspension, and

by said adding, producing a degree of particle agglutination which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the anaylte sample to a suspension of the particles in the absence of the liposomes.

2. The method of claim 1, wherein the liposomes are added such that the resulting reaction medium has a final liposome concentration of between about 10 micromolar and 1 millimolar.

3. The method of claim 1, wherein the liposomes are composed of lipid-bilayer vesicles in the 0.4 to 10 micron diameter size range.

4. The method of claim 1, wherein the agglutinatinable particles are latex particles.

5. The method of claim 1, wherein the analyte molecules include multivalent antigen molecules, and both the particle anti-analyte molecules and the analyte-binding molecules include anti-antigen antibody or antibody fragment molecules.

6. The method of claim 5, wherein the antigen includes hepatitis B surface antigen, and the antibody or antibody fragment molecules include anti-hepatitis B surface antigen antibodies.

7. The method of claim 1, wherein the analyte is an IgG, and the analyte-binding molecules, include protein A molecules.

8. The method of claim 7, wherein the analyte includes anti-nuclear antibody contained in a sample containing non-antigen specific immunoglobulins which are also recognized specifically by protein A.

9. The method of claim 1, wherein the analyte molecules include antibody molecules which bind immunospecifically to the particle anti-analyte molecules, and the analyte-binding molecules include binding proteins which bind specifically to the analyte antibody molecules.

10. The method of claim 9, wherein the analyte molecules include IgM molecules and the analyte-binding molecules include anti-IgM antibody or antibody fragment molecules covalently attached to the surface lipid components in the liposomes.

11. The method of claim 10, wherein the IgM molecules include rheumatoid factor.

22. The kit of claim 11 for use in determination of hepatitis B surface antigen, wherein the antibody or antibody fragment molecules include anti-hepatitis B surface antigen antibodies.

12. An enhanced agglutination assay kit for determination of a multivalent analyte in a weakly positive analyte-containing sample, comprising:

an unagglutinated suspension of (a) agglutinatinable particles between about 1 to 20 microns in size, and having surface-bound anti-analyte molecules adapted to promote particle agglutination in the presence of the analyte, and (b) liposomes having surface-bound analyte-binding molecules, at an average concentration of at least about 15 analyte-binding molecules per liposome, these molecules being effective to bind the analyte concurrently with analyte binding to a particle-bound anti-analyte molecule.

said liposomes being present in an amount effective to produce a degree of particle agglutination, when such analyte sample is added to the suspension, which is at least 1-2 grades greater, on a 1-4 grade scale, than that which would be produced by adding the analyte to a suspension of the particles in the absence of the liposomes.

13. The kit of claim 12, wherein the concentration of liposomes supplied is between about 20 micromolar and 1 millimolar in the reaction medium.

14. The kit of claim 12, wherein the liposomes are composed of lipid-bilayer vesicles in the 0.4 to 10 micron diameter size range.

15. The kit of claim 12, wherein the particles include polymeric beads, and the liposomes include more than about 20 mole percent of negatively charged lipid components.

16. The kit of claim 12 wherein the particles include red blood cells, and the liposomes include less than about 20 moles percent of negatively charged lipid components.

17. The kit of claim 12, wherein the agglutinatinable particles are latex particles.

18. The kit of claim 12, wherein the suspension further includes ribbon-like lipid bilayer structures formed by freezing and thawing liposomes.

19. The kit of claim 12 for use in determination of an antibody analyte, wherein the particle anti-analyte molecules and the analyte-binding molecules include binding proteins adapted to bind specifically to the molecules of the analyte antibody.

20. The kit of claim 19 for use in determination of an IgM analyte such as rheumatoid factor, wherein the particle anti-analyte molecules include IgG molecules, and the analyte-binding molecules include anti-IgM antibody or antibody fragment molecules covalently attached to surface lipid components in the liposomes.

21. The kit of claim 12, for use in determination of a multivalent antigen, wherein both the particle anti-analyte molecules and analyte-binding molecules include anti-antigen antibody or antibody fragment molecules.

23. The kit of claim 12, for use in determining an antigen-specific immunoglobulin which is recognized specifically by protein A and which is contained in a sample containing non-antigen-specific immunoglobulins which are recognized specifically by protein A, wherein the particles have surface-bound antigen molecules and the reagent analyte-binding molecules include protein A molecules.

24. The kit of claim 23, wherein the antigen includes anti-nuclear antibody.